- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05034991
The Role of Endometrial Blood Flow in Endometrial Cancer
March 27, 2023 updated by: Sheng-Mou Hsiao, Far Eastern Memorial Hospital
The incidence of endometrial cancer is gradually increasing nowaday.
Sonography can be used to evaluate the endometrial volume, the vascularity and the blood flow.
This study will analyze the role of preoperative endometrial blood flow in the outcome of endometrial cancer patients.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Taipei
-
Banqiao, New Taipei, Taiwan, 22050
- Recruiting
- Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
endometrial cancer patient
Description
Inclusion Criteria:
- >20 years old female had Endometrial cancer
Exclusion Criteria:
- <20 years old female
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between the endometrial vascularity (VFI, FI, VI), endometrial volume, endometrial thickness and progression-free survival of endometrial cancer patients
Time Frame: 12 months
|
Correlation between the endometrial vascularity (VFI, FI, VI), endometrial volume, endometrial thickness and progression-free survival of endometrial cancer patients
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 5, 2021
Primary Completion (Anticipated)
December 31, 2029
Study Completion (Anticipated)
December 31, 2029
Study Registration Dates
First Submitted
September 2, 2021
First Submitted That Met QC Criteria
September 2, 2021
First Posted (Actual)
September 5, 2021
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 27, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 109171-E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Ain Shams Maternity HospitalNot yet recruitingTreatment Endometrial Cancer
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Mayo ClinicRecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial CancerUnited States
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Not yet recruitingRecurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial CancerUnited States
-
Eli Lilly and CompanyGynecologic Oncology GroupCompletedNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium | Neoplasms, EndometrialUnited States
-
University of OklahomaCompletedEndometrial Cancer | Papillary Serous | Clear Cell Endometrial CancerUnited States
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael